IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.277
-0.008 (-2.63%)
Feb 27, 2026, 4:00 PM EST - Market closed
IGC Pharma Employees
IGC Pharma had 70 employees as of March 31, 2025. The number of employees increased by 3 or 4.48% compared to the previous year.
Employees
70
Change (1Y)
3
Growth (1Y)
4.48%
Revenue / Employee
$15,800
Profits / Employee
-$92,086
Market Cap
26.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Kyntra Bio | 225 |
| Boundless Bio | 64 |
| Passage Bio | 60 |
| Evaxion | 46 |
| AN2 Therapeutics | 22 |
| NeuroSense Therapeutics | 17 |
| BriaCell Therapeutics | 16 |
| Hyperion DeFi | 14 |
IGC News
- 2 days ago - IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research - Accesswire
- 4 days ago - IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - Accesswire
- 5 days ago - IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Accesswire
- 11 days ago - IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - Accesswire
- 16 days ago - IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Accesswire
- 18 days ago - IGC Pharma Announces Equity Research Update by Alliance Global Partners - Accesswire
- 19 days ago - IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center - Accesswire
- 26 days ago - IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation - Accesswire